Navigation Links
MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
Date:2/23/2009

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial did not meet its co-primary endpoints, asthma control as assessed by changes from baseline in nighttime and daytime composite symptom scores, in either of the doses evaluated, when compared with placebo. Median nebulization times were less than four minutes for both doses in the study. Initial review of the data has not identified any serious adverse events attributed to study drug. Patients continue to be treated in a 52-week safety study to collect long-term safety data on the two doses under investigation.

"Based on our initial review of these data, both the placebo and study groups experienced improvements in asthma symptoms, but the differences were not statistically significant. We observed a higher than expected response in the placebo group, starting as early as one week after randomization and continuing throughout the 12 week treatment period," said Timothy S. Nelson, Chief Executive Officer of MAP Pharmaceuticals. "We and our partner, AstraZeneca, are conducting further analyses of these data to determine appropriate next steps going forward for the program. The Company remains dedicated to developing therapies for children suffering from asthma."

About the AstraZeneca Collaboration

MAP Pharmaceuticals and AstraZeneca have a collaboration agreement to develop and commercialize UDB in the United States, and AstraZeneca has rights to develop and commercialize UDB outside of the United States.

About the Study

In this randomized, double-blind, placebo-controlled study, 360
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
2. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
3. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
4. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
5. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
10. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
11. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.275 (27.5 cents) per share on the corporation,s ... to holders of record on July 21, 2014. ... to helping people on their path to better health as ... States . Through the company,s more than 7,600 CVS/pharmacy ...
(Date:1/15/2014)... Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic ... . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... policy support, China,s orthopedic instrument ... total market size rising from 3.28 billion yuan in ...
(Date:1/15/2014)... Jan. 15, 2014 As health officials across the Midwest ... Meijer pharmacies in Michigan will offer ... patients, enabling Meijer pharmacists to administer tests and, in some ... a physician participating in the study. The ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... a voluntary nationwide recall of the three lots listed below of the following product: ... l oi de Injection , USP, 0 . ... V i alsN DC# 0 5 1 ... recall, initiated on March 15, 2011 to the User Level, is for the following lots of ...
... Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... testing, said today that it will showcase its ... with the military to develop earlier diagnosis of ... Awareness Day on Capitol Hill in Washington, D.C. ...
Cached Medicine Technology:American Regent Initiates Voluntary Nationwide Recall of Bacteriostatic Sodium Chloride Injection, USP, 0.9% 30 mL Multiple Dose Vials 2American Regent Initiates Voluntary Nationwide Recall of Bacteriostatic Sodium Chloride Injection, USP, 0.9% 30 mL Multiple Dose Vials 3Neuro Kinetics to Showcase I-Portal® Research at Brain Injury Awareness Day on Capitol Hill 2
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein ... Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents & ... studies the major market drivers, restraints, and opportunities ... of the World (RoW). , The proteomics market ... years, mainly due to the increasing need of ...
(Date:7/11/2014)... the best available treatment for patients, from a range ... for taxpayers than the existing clinical trial process, a ... carried out while he was a member of the ... based at The University of Manchester,s Health eResearch Centre, ... ) today (Friday 11 July) looked at the use ...
(Date:7/11/2014)... With the arrival of summer, VisitandCare.com ... surgery and hair transplant procedures, up 80 percent from ... of medical tourism destinations, the company is helping patients ... and achieve the look they have always desired. ... name in the medical tourism industry, VisitandCare.com is comprised ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Recently, Fadhits.com, the ... assortment of kids prom dresses . To bring more ... firm has also launched a special offer for these brand ... 25, 2014. , The company’s sales manager says gladly, “We ... this special offer is to acknowledge all new and old ...
(Date:7/11/2014)... Francisco shows that an "expressive therapy" group intervention ... with HIV disclose their health status and improves ... quality of their relationships., "Medication alone is totally ... Machtinger, MD, director of the Women,s HIV Program ... are on effective antiretroviral therapy but far too ...
Breaking Medicine News(10 mins):Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Promotion for Kids Prom Dresses Now Provided at Fadhits.com 2Health News:'Expressive therapy" intervention assists women living with HIV 2
... , MILLERSVILLE, Md., June 2 Travel Advantage Network ... spring morning to support the National Alliance for Research ... kilometers of it. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090602/DC26325 ) ... support the charity by completing a 2.5K sponsored walk at ...
... Royal Philips Electronics (NYSE: ... Trilogy100 portable at-home life-support ventilator. The highly versatile, ... milestone in home ventilation from a recognized leader in ... for noninvasive ventilation nearly 20 years ago. , ...
... 2 More than 17 million U.S. children live more ... a life-saving pediatric trauma center, according to a new study ... University of Pennsylvania . The creation of a national ... locations of gaps and greatly improve access to care for ...
... new procedure , TUESDAY, June ... involves sewing together the sides of the stomach holds ... suggest preliminary findings from a clinical trial. , The ... the stomach from relaxing to accept food. This reduces ...
... Pa., June 2 Governor Edward G. Rendell ... the Lottery-funded PACENET prescription drug benefit for older Pennsylvanians, providing ... no drug coverage now. , , "As older ... times, providing comprehensive prescription medication coverage is more important than ...
... Monitor for pest control operators helps control bed bug ... BioSensory, Inc., manufacturer of environmentally-sensitive pest management products ... insects, announces the release of its NightWatch(TM) Bedbug Monitor ... to use to detect bed bug infestations at the ...
Cached Medicine News:Health News:A Little Bit of Leg Work Goes a Long Way for Travel Advantage Network and Mental Health Charity 2Health News:Photos: Philips Expands Home Healthcare Commitment With Portable Life-Support Ventilator; Offers Ease of Use, Portability and Versatility for Patient 2Health News:Photos: Philips Expands Home Healthcare Commitment With Portable Life-Support Ventilator; Offers Ease of Use, Portability and Versatility for Patient 3Health News:17 Million U.S. Children Live More Than an Hour Away From Trauma Care 2Health News:17 Million U.S. Children Live More Than an Hour Away From Trauma Care 3Health News:Weight-Loss Surgery Simplified 2Health News:Governor Rendell Proposes Offering Prescription Help to 30,000 More Older Adults as Part of Plan to Save $60 Million 2Health News:New Product Detects Early Bed Bug Infestations 2Health News:New Product Detects Early Bed Bug Infestations 3
Inquire...
... These high-power, apochromatically corrected ... satisfy the most exacting ... They are suitable for ... to 25 mm and ...
... a higher numerical aperture and superior contrast. ... surface,reflections and provides an image with higher ... fluorescence, brightfield and DIC observation techniques. This ... allows it to be used with immersion ...
The KL 2500 LCD is Schott's most powerful cold light source which makes it ideal for special applications. A 250W halogen reflector lamp provides more than twice as much light as the KL 1500 LCD....
Medicine Products: